- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Ramsey Today
By the People, for the People
Marathon Capital Management Boosts Stake in ADMA Biologics
Institutional investor increases holdings in biotech company by 64.5% in Q3
Mar. 14, 2026 at 10:56am
Got story updates? Submit your updates here. ›
Marathon Capital Management, an institutional investor, has increased its stake in ADMA Biologics Inc. (NASDAQ:ADMA) by 64.5% in the third quarter. The firm now owns 466,570 shares of the biotechnology company's stock, worth approximately $6.84 million, making it the 18th largest position in its portfolio.
Why it matters
ADMA Biologics is a biopharmaceutical company focused on the development and commercialization of specialty plasma-derived biologics. The increase in Marathon Capital Management's stake suggests the firm sees potential in ADMA's business and growth prospects.
The details
According to a disclosure with the Securities and Exchange Commission, Marathon Capital Management acquired an additional 182,880 shares of ADMA Biologics in the third quarter, bringing its total position to 466,570 shares. This represents about 0.20% of ADMA's outstanding shares. The firm cited ADMA's position in the specialty plasma-derived biologics market as a key factor behind the increased investment.
- Marathon Capital Management disclosed its increased stake in ADMA Biologics in a filing with the SEC in the third quarter of 2026.
The players
Marathon Capital Management
An institutional investor that manages a portfolio of investments, including a position in ADMA Biologics.
ADMA Biologics Inc.
A biopharmaceutical company focused on the development and commercialization of specialty plasma-derived biologics.
The takeaway
The increased investment by Marathon Capital Management in ADMA Biologics suggests the firm sees long-term potential in the company's specialty plasma-derived biologics business. This could signal growing institutional interest in ADMA as it continues to develop and commercialize its product portfolio.
